ElutiaELUT
ELUT
About: Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Employees: 51
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
10% more funds holding
Funds holding: 29 [Q3] → 32 (+3) [Q4]
6% more capital invested
Capital invested by funds: $46.7M [Q3] → $49.3M (+$2.59M) [Q4]
2.61% more ownership
Funds ownership: 40.98% [Q3] → 43.59% (+2.61%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
365%
upside
Avg. target
$8
365%
upside
High target
$8
365%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Frank Takkinen 23% 1-year accuracy 5 / 22 met price target | 365%upside $8 | Buy Maintained | 9 May 2025 |
Cantor Fitzgerald Ross Osborn 30% 1-year accuracy 12 / 40 met price target | 365%upside $8 | Overweight Reiterated | 7 Mar 2025 |
Financial journalist opinion
Based on 6 articles about ELUT published over the past 30 days
Neutral
Seeking Alpha
6 days ago
Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript
Elutia Inc. (NASDAQ:ELUT ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Matt Steinberg - FINN Partners Randal Mills - Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Matt Park - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen. Welcome to the Elutia First Quarter 2025 Financial Results Conference Call.
Neutral
GlobeNewsWire
1 week ago
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m.
Neutral
GlobeNewsWire
2 weeks ago
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly capture top-line revenue and should improve the gross margin and profitability of this product segment.
Neutral
GlobeNewsWire
2 weeks ago
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
Neutral
GlobeNewsWire
3 weeks ago
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29
SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia's Chief Scientific Officer, will participate in Chardan's Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.
Neutral
GlobeNewsWire
3 weeks ago
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice
— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro's utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practice.
Neutral
GlobeNewsWire
1 month ago
Elutia Confirms No Material Impact from Global Tariffs
SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has had no material impact on its commercial or operational performance.
Neutral
GlobeNewsWire
1 month ago
Elutia to Participate in Upcoming Investor Conferences
SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
1 month ago
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes
Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society's annual meeting (HRS 2025).
Neutral
GlobeNewsWire
1 month ago
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
Seventh GPO Agreement Signed Since EluPro's Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Advantus Health Partners (“Advantus”), to provide access of Elutia's EluPro™ Antibiotic Eluting BioEnvelope to Advantus' core group purchasing organizations (GPO) solutions portfolio.
Charts implemented using Lightweight Charts™